Nancy J. Leith

Array ( [id] => 18485273 [patent_doc_number] => 20230212606 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-06 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING KCNQ4-ASSOCIATED HEARING LOSS [patent_app_type] => utility [patent_app_number] => 17/923636 [patent_app_country] => US [patent_app_date] => 2021-05-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 85502 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -96 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17923636 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17292191 [patent_doc_number] => 20210388030 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-16 [patent_title] => COMPOSITIONS AND METHODS FOR INTRAVITREAL DELIVERY OF POLYNUCLEOTIDES TO RETINAL CONES [patent_app_type] => utility [patent_app_number] => 17/308785 [patent_app_country] => US [patent_app_date] => 2021-05-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26644 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17308785 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18511674 [patent_doc_number] => 20230227856 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-20 [patent_title] => SELECTION BY ESSENTIAL-GENE KNOCK-IN [patent_app_type] => utility [patent_app_number] => 17/923358 [patent_app_country] => US [patent_app_date] => 2021-05-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 111475 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -212 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17923358 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18420473 [patent_doc_number] => 20230174935 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-08 [patent_title] => REPEAT DOSING OF HYPOIMMUNOGENIC CELLS [patent_app_type] => utility [patent_app_number] => 17/997103 [patent_app_country] => US [patent_app_date] => 2021-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 55602 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -250 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17997103 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17050768 [patent_doc_number] => 20210260202 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-26 [patent_title] => Methods and Compositions Related to Annexin 1-Binding Compounds [patent_app_type] => utility [patent_app_number] => 17/240714 [patent_app_country] => US [patent_app_date] => 2021-04-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33098 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17240714 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17255766 [patent_doc_number] => 20210368751 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-02 [patent_title] => HUMANIZED RODENTS THAT EXPRESS HEAVY CHAIN CONTAINING VL DOMAINS [patent_app_type] => utility [patent_app_number] => 17/224524 [patent_app_country] => US [patent_app_date] => 2021-04-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 53415 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17224524 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17242035 [patent_doc_number] => 20210361778 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-25 [patent_title] => ADENO-ASSOCIATED VIRUS COMPOSITIONS FOR IDS GENE TRANSFER AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/222659 [patent_app_country] => US [patent_app_date] => 2021-04-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37035 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17222659 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17067590 [patent_doc_number] => 20210269805 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-02 [patent_title] => Transcription Factor Trapping by RNA in Gene Regulatory Elements [patent_app_type] => utility [patent_app_number] => 17/217612 [patent_app_country] => US [patent_app_date] => 2021-03-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 53489 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17217612 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19281893 [patent_doc_number] => 20240218367 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-04 [patent_title] => Targeted Destruction of Viral RNA by CRISPR-Cas13 [patent_app_type] => utility [patent_app_number] => 17/907121 [patent_app_country] => US [patent_app_date] => 2021-03-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 62431 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -51 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17907121 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18322937 [patent_doc_number] => 20230121065 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-20 [patent_title] => METHOD OF DELIVERING NUCLEIC ACID TO IMMUNE CELLS USING RBCEV [patent_app_type] => utility [patent_app_number] => 17/914194 [patent_app_country] => US [patent_app_date] => 2021-03-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23304 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17914194 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18842642 [patent_doc_number] => 20230405046 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-21 [patent_title] => ANTIGEN-SPECIFIC T CELL RECEPTORS AND T CELL EPITOPES [patent_app_type] => utility [patent_app_number] => 17/906448 [patent_app_country] => US [patent_app_date] => 2021-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45280 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17906448 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18308175 [patent_doc_number] => 20230112075 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-13 [patent_title] => COMPOSITIONS AND METHODS FOR MODIFYING A TARGET NUCLEIC ACID [patent_app_type] => utility [patent_app_number] => 17/911387 [patent_app_country] => US [patent_app_date] => 2021-03-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15007 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17911387 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17168908 [patent_doc_number] => 20210322578 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-21 [patent_title] => ONCOLYTIC VACCINIA VIRUS CANCER THERAPY [patent_app_type] => utility [patent_app_number] => 17/200725 [patent_app_country] => US [patent_app_date] => 2021-03-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44574 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17200725 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18786095 [patent_doc_number] => 20230374085 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-23 [patent_title] => DUAL-TARGETING CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS COMPRISING IL-13 AND CHLOROTOXIN FOR CANCER TREATMENT [patent_app_type] => utility [patent_app_number] => 17/910459 [patent_app_country] => US [patent_app_date] => 2021-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8756 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17910459 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16948458 [patent_doc_number] => 20210207149 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-08 [patent_title] => INCREASED NUCLEIC ACID-GUIDED CELL EDITING VIA A LEXA-RAD51 FUSION PROTEIN [patent_app_type] => utility [patent_app_number] => 17/199413 [patent_app_country] => US [patent_app_date] => 2021-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25803 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 182 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17199413 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18324098 [patent_doc_number] => 20230122226 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-20 [patent_title] => CRISPR/CAS9 SYSTEM FOR MULTISTRAIN HIV-1 TREATMENT [patent_app_type] => utility [patent_app_number] => 17/905407 [patent_app_country] => US [patent_app_date] => 2021-03-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10836 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -81 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17905407 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16948402 [patent_doc_number] => 20210207093 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-08 [patent_title] => GENETICALLY-MODIFIED CELLS COMPRISING A MODIFIED HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE [patent_app_type] => utility [patent_app_number] => 17/189243 [patent_app_country] => US [patent_app_date] => 2021-03-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34761 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17189243 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18351332 [patent_doc_number] => 20230139443 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-04 [patent_title] => TREATING AUTOSOMAL DOMINANT BESTROPHINOPATHIES AND METHODS FOR EVALUATING SAME [patent_app_type] => utility [patent_app_number] => 17/904899 [patent_app_country] => US [patent_app_date] => 2021-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19225 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -48 [patent_words_short_claim] => 84 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17904899 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18308668 [patent_doc_number] => 20230112568 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-13 [patent_title] => TREATING AUTOSOMAL RECESSIVE BESTROPHINOPATHIES AND METHODS FOR EVALUATING SAME [patent_app_type] => utility [patent_app_number] => 17/904903 [patent_app_country] => US [patent_app_date] => 2021-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18410 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -38 [patent_words_short_claim] => 72 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17904903 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18310405 [patent_doc_number] => 20230114305 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-13 [patent_title] => RECOMBINANT MYXOMA VIRUSES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/801206 [patent_app_country] => US [patent_app_date] => 2021-02-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23526 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -74 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17801206 [rel_patent_id] =>[rel_patent_doc_number] =>)